Notícias e Atividades da Biomarin Pharmaceutical

Biomarin Pharmaceutical é uma das ...

• Global Fortune 500 (#948);
• Russell 3000;
• TOB Iconic 10,000.

Biomarin Pharmaceutical é uma empresa listada sob o símbolo BMRN (US).

Fusão, aquisição e financiamento envolvendo Biomarin Pharmaceutical.

• Biomarin Pharmaceutical has announced the acquisition of Inozyme  (publicado em 29 de maio de 2025).

Veja o organograma con seus 29 executivos principais

Biografias mais buscadas da Biomarin Pharmaceutical

• Alexander Hardy, Chief Executive Officer and President
• Willard Dere, Director
• Robert Hombach, Director

Recentes movimentos de executivos em Biomarin Pharmaceutical

• Timothy Walbert, ingressou na Companhia como Director  (Notícia publicada em 26 de fevereiro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Biomarin Pharmaceutical.

Biomarin Pharmaceutical possui 1.838 concorrentes concorrentes Pfizer (Estados Unidos), Johnson & Johnson (Estados Unidos) e Sanofi (França).

Popular M&A news in Farmacêutica

• Pathos se torna um unicórnio com sua arrecadação de fundos de 365 milhões de dólares. (publicado em 4 de julho de 2025).
• Vor Biopharma and Incyte have announced they will merge  (publicado em 30 de junho de 2025)..
• Supernus Pharmaceuticals has announced the acquisition of Sage Therapeutics  (publicado em 16 de junho de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Linh Kha - Senior Vice President and General Manager, Japan Asia-Pacific da Amgen
• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Seth Harrison - Chairman and Director da Braeburn Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Biomarin Pharmaceutical

• BioMarin Announces Completion of Acquisition of Inozyme
• BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress
• BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
• BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings
• BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance
• BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET
• BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria
• BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clini
• BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA
• BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance
• View more press releases Close

Redes sociais sobre Biomarin Pharmaceutical

• Biomarin Pharmaceutical na Wikipedia, Google News e Yahoo Finance
• Biomarin Pharmaceutical na LinkedIn, Twitter e YouTube